Clinical Trial Update: NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Early Feasibility Study [NA]

View source ↗

Summary

NHLBI's SESAME early feasibility trial evaluating septal scoring along the midline endocardium in hypertrophic cardiomyopathy and related valve diseases was ter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aortic Valve Stenosis
• Hypertrophic Cardiomyopathy
• Left Ventricular Septal Hypertrophy
• Mitral Valve Disease

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Hypertrophic Cardiomyopathy, Left Ventricular Septal Hypertrophy | NA | Status: TERMINATED | Results posted: 2025-12-18